

HR 321

Neuromyelitis Optica Consortium Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 8, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jan 25, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/321>

Sponsor

Name: Rep. Lee, Barbara [D-CA-13]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 25, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jan 8, 2019)

Neuromyelitis Optica Consortium Act

This bill requires the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis.

The consortium must

- award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO;
- assemble a panel of experts to provide guidance and recommendations on research design and protocols; and
- designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.

Actions Timeline

- **Jan 25, 2019:** Referred to the Subcommittee on Health.
- **Jan 8, 2019:** Introduced in House
- **Jan 8, 2019:** Referred to the House Committee on Energy and Commerce.